Table 3. Pretreatment Clinical and... | American Society of Hematology

Table 3.

Pretreatment Clinical and Hematologic Findings and Responses to 4 Months of Therapy in Patients Randomized to Parenteral Cyanocobalamin

Patient No.	Age/Sex	Diagnosis^*	Therapy^†	Hematocrit (%)		MCV (fL)		Neurologic Symptoms^2-153
Patient No.	Age/Sex	Diagnosis^*	Therapy^†	Pre^‡	4 mo^‡	Pre	4 mo	Pre	4 mo
19	70/M	AG	IM	45	45	103	82	Ataxia	Cleared
20	70/M	AG	IM	40	45	118	86	Paresthesias	Improved
21	41/F	AG	IM	30^2-155	43^2-155	91	83
22	83/F	AG	IM	42	41	106	89	Memory loss	Improved
23	65/F	PA	IM	38¶	44¶	119	89
24	60/F	PA	IM	39	41	112	94
25	70/F	AG	IM	42	44	106	86
26	85/F	IR	IM	38	34	99	90	Ataxia	Cleared
27	77/F	AG	IM	42	45	100	98
28	73/F	Diet	IM	35	34	93	93
29	79/F	Diet	IM	41	43	107	106
30	37/F	GS	IM	30^2-155	37^2-155	129^2-155	86^2-155
31	85/F	OMEP	IM	39	41	84	86
32	78/F	IR	IM	38	37	86	91
33	85/F	AG	IM	35	34	100	97
Mean ± SD	71 ± 15		IM	39.5 ± 2.9	40.6 ± 4.4	102 ± 11	91 ± 7

Patient No.	Age/Sex	Diagnosis^*	Therapy^†	Hematocrit (%)		MCV (fL)		Neurologic Symptoms^2-153
Patient No.	Age/Sex	Diagnosis^*	Therapy^†	Pre^‡	4 mo^‡	Pre	4 mo	Pre	4 mo
19	70/M	AG	IM	45	45	103	82	Ataxia	Cleared
20	70/M	AG	IM	40	45	118	86	Paresthesias	Improved
21	41/F	AG	IM	30^2-155	43^2-155	91	83
22	83/F	AG	IM	42	41	106	89	Memory loss	Improved
23	65/F	PA	IM	38¶	44¶	119	89
24	60/F	PA	IM	39	41	112	94
25	70/F	AG	IM	42	44	106	86
26	85/F	IR	IM	38	34	99	90	Ataxia	Cleared
27	77/F	AG	IM	42	45	100	98
28	73/F	Diet	IM	35	34	93	93
29	79/F	Diet	IM	41	43	107	106
30	37/F	GS	IM	30^2-155	37^2-155	129^2-155	86^2-155
31	85/F	OMEP	IM	39	41	84	86
32	78/F	IR	IM	38	37	86	91
33	85/F	AG	IM	35	34	100	97
Mean ± SD	71 ± 15		IM	39.5 ± 2.9	40.6 ± 4.4	102 ± 11	91 ± 7

*See footnotes to Table 1. GS indicates prior gastric stapling. All patients designated as AG or PA had low serum pepsinogen levels as well as elevated serum gastrin concentrations.

†

IM indicates intramuscular cobalamin therapy.

‡

Pre indicates pretreatment value. 4 mo indicates value after 4 months of intramuscular cyanocobalamin (total of nine 1,000 μg injections).

F2-153

See footnote to Table 1.

F2-155

Patient no. 21 received simultaneous iron therapy and patient no. 30 received simultaneous iron and folic acid treatment. Hematocrits on patients no. 21 and 30 are not included in the calculation of the mean values and the MCV of patient no. 30 was not included in the calculation of the mean values.

¶Also had atrophic glossitis before therapy, which had resolved completely at 4 months.

View Large

This Feature Is Available To Subscribers Only